Singapore markets closed

Arcturus Therapeutics Holdings Inc. (ARCT)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
39.73+0.97 (+2.50%)
At close: 04:00PM EST
39.00 -0.73 (-1.84%)
After hours: 08:00PM EST
Full screen
Trade prices are not sourced from all markets
Previous close38.76
Open38.82
Bid38.08 x 800
Ask41.40 x 900
Day's range38.77 - 40.48
52-week range14.21 - 43.81
Volume589,325
Avg. volume403,621
Market cap1.062B
Beta (5Y monthly)2.62
PE ratio (TTM)10.57
EPS (TTM)3.76
Earnings date07 Mar 2024
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est65.25
  • Business Wire

    Arcturus Therapeutics to Present at the Barclays 26th Annual Global Healthcare Conference

    SAN DIEGO, February 26, 2024--Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a global late-stage clinical messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases, today announced that the Company will present at a Fireside Chat hosted by Barclays 26th Annual Global Healthcare Conference in Miami, on Thursday, March 14, 2024, at 11:45 a.m. Eastern Time.

  • Business Wire

    Arcturus Therapeutics Receives Orphan Medicinal Product Designation from the European Commission (EC), for ARCT-032, for the Treatment of Cystic Fibrosis

    SAN DIEGO, February 22, 2024--Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a global late-stage clinical messenger RNA medicines company focused on the development of infectious disease vaccines and medicines to treat unmet medical needs within liver and respiratory rare diseases, today announced that the European Commission (EC), based on a positive opinion issued by the European Medicines Agency (EMA), has granted orphan medicinal product designation for the Co

  • Business Wire

    Arcturus Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Corporate Update on March 7, 2024

    SAN DIEGO, February 20, 2024--Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a global late-stage clinical messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases, today announced that it will release its financial results for the quarter and year ended December 31, 2023 after the market close on Thursday, March 7 and will also host a conference call and webca